Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 7/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005359 | 1.00 | CSF1R (0.42) | CSF1RKCNH3TTKRIPK2GPR142 | |
| SCHEMBL3005364 | 1.00 | CSF1R (0.42) | CSF1RKCNH3TTKRIPK2GPR142 | |
| SCHEMBL1278017 | 0.85 | KCNH3 (0.36) | CSF1RKCNH3TTKRIPK2CREBBP | |
| SCHEMBL1278019 | 0.85 | KCNH3 (0.36) | CSF1RKCNH3TTKRIPK2CREBBP | |
| SCHEMBL3023986 | 0.85 | TTK (0.40) | CSF1RKCNH3TTKRIPK2CYP3A4 | |
| SCHEMBL1278101 | 0.85 | TTK (0.40) | CSF1RKCNH3TTKRIPK2CYP3A4 | |
| SCHEMBL1278098 | 0.85 | TTK (0.40) | CSF1RKCNH3TTKRIPK2CYP3A4 | |
| SCHEMBL3019937 | 0.84 | RIPK2 (0.34) | CSF1RKCNH3TTKRIPK2CREBBP | |
| SCHEMBL3029306 | 0.84 | CSF1R (0.33) | CSF1RKCNH3CCNKCDK9CYP3A4 | |
| SCHEMBL3029304 | 0.84 | CSF1R (0.33) | CSF1RKCNH3CCNKCDK9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | claimed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | claimed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | claimed |
| CN-101952281-A | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD | 2011-01-19 | — | — | CN | claimed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | claimed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | claimed |
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | disclosed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | disclosed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| CN-101952281-A | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD | 2011-01-19 | — | — | CN | disclosed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | CSF1R 2444/4885KCNH3 482/4885TTK 2085/4885 |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | CSF1R 2444/4885KCNH3 482/4885TTK 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.